Ultram and Oral intake reduced - a phase IV clinical study of FDA data

Summary:

Oral intake reduced is reported as a side effect among people who take Ultram (tramadol hydrochloride), especially for people who are female, 40-49 old, also take Peg-Intron, and have Hepatitis c.

The phase IV clinical study analyzes which people have Oral intake reduced when taking Ultram. It is created by eHealthMe based on reports of 26,802 people who have side effects when taking Ultram from the FDA, and is updated regularly.

What is Ultram?

Ultram has active ingredients of tramadol hydrochloride. It is often used in pain. eHealthMe is studying from 28,425 Ultram users. Check the latest studies of Ultram.

What is Oral intake reduced?

Oral intake reduced is found to be associated with 397 drugs and 664 conditions by eHealthMe. Check the latest studies of Oral intake reduced.

On Jul, 15, 2026

26,802 people reported to have side effects when taking Ultram.
Among them, 19 people (0.07%) have Oral intake reduced.

Among these 19 people:

What is the gender of people who have Oral intake reduced when taking Ultram? *

female: 63.16 %
male: 36.84 %

What is the age of people who have Oral intake reduced when taking Ultram? *

What are other drugs people take besides Ultram? *

What are other side effects people have besides Oral intake reduced? *

Nausea (feeling of having an urge to vomit): 10 people, 52.63%
Diarrhea: 9 people, 47.37%
Acute Kidney Failure: 9 people, 47.37%
Nausea And Vomiting: 9 people, 47.37%
Blood Glucose Increased: 8 people, 42.11%
Dehydration (dryness resulting from the removal of water): 8 people, 42.11%
Hypotension (abnormally low blood pressure): 6 people, 31.58%
Drowsiness: 6 people, 31.58%
Thrombocytopenia (decrease of platelets in blood): 6 people, 31.58%
Confusional State: 6 people, 31.58%

What are the existing conditions these people have? *

Hepatitis C: 8 people, 42.11%
Cough: 3 people, 15.79%
Peripheral Neuropathy (damage to nerves of the peripheral nervous system): 2 people, 10.53%
Depression: 2 people, 10.53%
Wound: 1 person, 5.26%
High Blood Cholesterol: 1 person, 5.26%
Chronic Hepatitis (long lasting inflammation of liver): 1 person, 5.26%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 5.26%
Diabetes: 1 person, 5.26%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Ultram and have Oral intake reduced?

- Check whether Oral intake reduced is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ultram:

Ultram (28,425 reports)

Browse all side effects of Ultram:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Oral intake reduced:

Oral intake reduced (397 drugs)

Browse all the conditions that are associated with Oral intake reduced:

Oral intake reduced (664 conditions)

Related publications that referenced our studies

Mansour HM, "Tramadol and Disseminated Intravascular Coagulopathy: A Case Report", Medicine Science, 2015 Jan .
Mansour HM, "Tramadol and Disseminated Intravascular Coagulopathy: A Case Report", Medicine Science, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on tramadol hydrochloride (the active ingredients of Ultram) and Ultram (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.